Smoking cessation medication prescriptions in patients with T2DM and TUD
(Comparision between matched semaglutide vs other anti–diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
5,954	semaglutide	insulins	242 (4.1%)	670 (11.3%)	−7.2% (−8.1%, −6.2%)		0.32 (0.28−0.38)
5,955	semaglutide	metformin	244 (4.1%)	428 (7.2%)	−3.1% (−3.9%, −2.3%)		0.55 (0.47−0.65)
4,831	semaglutide	DPP−4i	187 (3.9%)	372 (7.7%)	−3.8% (−4.8%, −2.9%)		0.48 (0.40−0.57)
5,325	semaglutide	SGLT2i	211 (4.0%)	369 (6.9%)	−3.0% (−3.8%, −2.1%)		0.55 (0.46−0.65)
5,388	semaglutide	SU	215 (4.0%)	418 (7.8%)	−3.8% (−4.7%, −2.9%)		0.49 (0.42−0.58)
2,659	semaglutide	TZD	81 (3.0%)	159 (6.0%)	−2.9% (−4.0%, −1.8%)		0.49 (0.37−0.63)
5,337	semaglutide	other GLP−1RAs	212 (4.0%)	331 (6.2%)	−2.2% (−3.1%, −1.4%)		0.62 (0.52−0.74)

0.30 0.40   0.60 0.801.0   2.0   3.00

Hazard Ratio (HR)